Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Human papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2015

Human papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Human papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2015', provides an overview of the Human papillomavirus (HPV) Associated Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Human papillomavirus (HPV) Associated Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Human papillomavirus (HPV) Associated Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Human papillomavirus (HPV) Associated Cancer-Overview 11

Pipeline Products for Human papillomavirus (HPV) Associated Cancer-Comparative Analysis 12

Human papillomavirus (HPV) Associated Cancer-Therapeutics under Development by Companies 13

Human papillomavirus (HPV) Associated Cancer-Therapeutics under Investigation by Universities/Institutes 16

Human papillomavirus (HPV) Associated Cancer-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Human papillomavirus (HPV) Associated Cancer-Products under Development by Companies 20

Human papillomavirus (HPV) Associated Cancer-Products under Investigation by Universities/Institutes 22

Human papillomavirus (HPV) Associated Cancer-Companies Involved in Therapeutics Development 23

3SBio Inc. 23

Abivax 24

Admedus Ltd 25

Antigen Express, Inc. 26

Bionor Pharma ASA 27

Cancer Therapeutics CRC Pty Ltd 28

Etubics Corporation 29

EyeGene, Inc. 30

Formune S.L. 31

Genexine, Inc. 32

iBio, Inc. 33

Inovio Pharmaceuticals, Inc. 34

MedImmune, LLC 35

Merck & Co., Inc. 36

Novartis AG 37

Onconova Therapeutics, Inc. 38

Prima BioMed Ltd. 39

Profectus BioSciences, Inc. 40

Redbiotec AG 41

Sirnaomics, Inc. 42

Theravectys S.A. 43

Transgene SA 44

Vaccibody AS 45

Virometix AG 46

ViroStatics, srl 47

Human papillomavirus (HPV) Associated Cancer-Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Combination Products 49

Assessment by Target 50

Assessment by Mechanism of Action 52

Assessment by Route of Administration 54

Assessment by Molecule Type 56

Drug Profiles 58

ABX-318-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

AEH-10p-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

alpelisib-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Antibodies to Target E6 for HPV Associated Cancer-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Antibodies to Target E7 for HPV Associated Cancer-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Cell Therapy to Target HPV-16 E6 Protein for Papillomavirus Associated Cancers-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

durvalumab + tremelimumab-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

EDA-HPVE7-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

EG-HPV-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Gene Therapy for Papillomavirus Associated Cervical Carcinoma-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

GX-188E-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

HPV Vaccine-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

human papillomavirus (7-valent) vaccine-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

human papillomavirus (9-valent) vaccine-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

human papillomavirus [Serotype 16] vaccine-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

human papillomavirus vaccine-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

human papillomavirus vaccine-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

INO-3106-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

INO-3112-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

RBT-201-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

rigosertib sodium-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

SSS-08-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

STP-909-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

STP-911-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

TG-4001-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Vacc-HPV-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Vaccine for HPV Associated Cancer-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Vaccine for HPV Associated Cancers-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Vaccine for HPV Associated Cancers-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Vaccine for HPV Associated Head and Neck Cancer-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Vaccine for HPV Associated Skin Cancer-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Vaccines for HPV Associated Cervical Cancer-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

VB-1016-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Vicoryx-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

Human papillomavirus (HPV) Associated Cancer-Recent Pipeline Updates 105

Human papillomavirus (HPV) Associated Cancer-Dormant Projects 115

Human papillomavirus (HPV) Associated Cancer-Product Development Milestones 116

Featured News & Press Releases 116

Dec 10, 2014: FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV 116

Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza 117

Nov 04, 2013: Merck's Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study 117

Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 119

Appendix 120

Methodology 120

Coverage 120

Secondary Research 120

Primary Research 120

Expert Panel Validation 120

Contact Us 120

Disclaimer 121

List of Tables

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2015 11

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Human papillomavirus (HPV) Associated Cancer-Pipeline by 3SBio Inc., H1 2015 23

Human papillomavirus (HPV) Associated Cancer-Pipeline by Abivax, H1 2015 24

Human papillomavirus (HPV) Associated Cancer-Pipeline by Admedus Ltd, H1 2015 25

Human papillomavirus (HPV) Associated Cancer-Pipeline by Antigen Express, Inc., H1 2015 26

Human papillomavirus (HPV) Associated Cancer-Pipeline by Bionor Pharma ASA, H1 2015 27

Human papillomavirus (HPV) Associated Cancer-Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2015 28

Human papillomavirus (HPV) Associated Cancer-Pipeline by Etubics Corporation, H1 2015 29

Human papillomavirus (HPV) Associated Cancer-Pipeline by EyeGene, Inc., H1 2015 30

Human papillomavirus (HPV) Associated Cancer-Pipeline by Formune S.L., H1 2015 31

Human papillomavirus (HPV) Associated Cancer-Pipeline by Genexine, Inc., H1 2015 32

Human papillomavirus (HPV) Associated Cancer-Pipeline by iBio, Inc., H1 2015 33

Human papillomavirus (HPV) Associated Cancer-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 34

Human papillomavirus (HPV) Associated Cancer-Pipeline by MedImmune, LLC, H1 2015 35

Human papillomavirus (HPV) Associated Cancer-Pipeline by Merck & Co., Inc., H1 2015 36

Human papillomavirus (HPV) Associated Cancer-Pipeline by Novartis AG, H1 2015 37

Human papillomavirus (HPV) Associated Cancer-Pipeline by Onconova Therapeutics, Inc., H1 2015 38

Human papillomavirus (HPV) Associated Cancer-Pipeline by Prima BioMed Ltd., H1 2015 39

Human papillomavirus (HPV) Associated Cancer-Pipeline by Profectus BioSciences, Inc., H1 2015 40

Human papillomavirus (HPV) Associated Cancer-Pipeline by Redbiotec AG, H1 2015 41

Human papillomavirus (HPV) Associated Cancer-Pipeline by Sirnaomics, Inc., H1 2015 42

Human papillomavirus (HPV) Associated Cancer-Pipeline by Theravectys S.A., H1 2015 43

Human papillomavirus (HPV) Associated Cancer-Pipeline by Transgene SA, H1 2015 44

Human papillomavirus (HPV) Associated Cancer-Pipeline by Vaccibody AS, H1 2015 45

Human papillomavirus (HPV) Associated Cancer-Pipeline by Virometix AG, H1 2015 46

Human papillomavirus (HPV) Associated Cancer-Pipeline by ViroStatics, srl, H1 2015 47

Assessment by Monotherapy Products, H1 2015 48

Assessment by Combination Products, H1 2015 49

Number of Products by Stage and Target, H1 2015 51

Number of Products by Stage and Mechanism of Action, H1 2015 53

Number of Products by Stage and Route of Administration, H1 2015 55

Number of Products by Stage and Molecule Type, H1 2015 57

Human papillomavirus (HPV) Associated Cancer Therapeutics-Recent Pipeline Updates, H1 2015 105

Human papillomavirus (HPV) Associated Cancer-Dormant Projects, H1 2015 115

List of Figures

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2015 11

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 48

Number of Products by Top 10 Targets, H1 2015 50

Number of Products by Stage and Top 10 Targets, H1 2015 50

Number of Products by Top 10 Mechanism of Actions, H1 2015 52

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 53

Number of Products by Top 10 Routes of Administration, H1 2015 54

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 55

Number of Products by Top 10 Molecule Types, H1 2015 56

Number of Products by Stage and Top 10 Molecule Types, H1 2015 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc.

Abivax

Admedus Ltd

Antigen Express, Inc.

Bionor Pharma ASA

Cancer Therapeutics CRC Pty Ltd

Etubics Corporation

EyeGene, Inc.

Formune S.L.

Genexine, Inc.

iBio, Inc.

Inovio Pharmaceuticals, Inc.

MedImmune, LLC

Merck & Co., Inc.

Novartis AG

Onconova Therapeutics, Inc.

Prima BioMed Ltd.

Profectus BioSciences, Inc.

Redbiotec AG

Sirnaomics, Inc.

Theravectys S.A.

Transgene SA

Vaccibody AS

Virometix AG

ViroStatics, srl

Human papillomavirus (HPV) Associated Cancer Therapeutic Products under Development, Key Players in Human papillomavirus (HPV) Associated Cancer Therapeutics, Human papillomavirus (HPV) Associated Cancer Pipeline Overview, Human papillomavirus (HPV) Associated Cancer Pipeline, Human papillomavirus (HPV) Associated Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com